Entrectinib for ROS1‐rearranged non‐small cell lung cancer after crizotinib‐induced interstitial lung disease: A case report

Chromosomal rearrangements involving the c‐ros oncogene 1 (ROS1) are identified in approximately 1% of non‐small cell lung cancer (NSCLC) patients. Crizotinib is the first tyrosine kinase inhibitor (TKI) against ROS1‐rearranged NSCLC. G2032R, a secondary resistant mutation, is observed in 41% of pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanimura, Mai, Kataoka, Nobutaka, Kunimatsu, Yusuke, Tsutsumi, Rei, Sato, Izumi, Nakano, Takayuki, Tanimura, Keiko, Takeda, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488445/
https://www.ncbi.nlm.nih.gov/pubmed/34631105
http://dx.doi.org/10.1002/rcr2.857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488445/
https://www.ncbi.nlm.nih.gov/pubmed/34631105
http://dx.doi.org/10.1002/rcr2.857

Ejemplares similares